Occam Recruits Brent Warner as CEO for Protego Biopharma
.jpg)
In April 2024, Occam placed Brent Warner as CEO of Protego Biopharma, a preclinical-stage biotech with science out of Jeff Kelly’s lab at Scripps, dedicated to finding novel solutions for protein misfolding diseases. The company is backed by MPM, Lightspeed Venture Partners, and Vida Ventures.
Brent joins Protego Biopharma with over 15 years of biopharmaceutical experience across rare diseases, gene therapy, and other therapeutic categories. He was previously the President of Gene Therapy at Poseida Therapeutics (NASDAQ: PSTX), where he was responsible for leading the research and pre-clinical development of non-viral gene therapy programs and platform technologies for genetic diseases. Prior to his role at Poseida, Warner held various positions across the industry, including VP of Gene Therapy and Rare Diseases at Novartis, a U.S. commercial leader in Hemophilia A at BioMarin Pharmaceuticals, and various strategic and operational roles across Hematology, Immunology, Oncology, and Medical Devices at Baxalta (now a wholly owned subsidiary of Takeda).
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.